10/26/2019
2019 Lung Infection Symposium - Fayed IV 1
NTM Standard Treatment and New Therapy 2019
Mohamed A Fayed, MD
Pulmonary critical care faculty
UCSF Fresno
Disclosure
Speaker for Insmed Inc.
10/26/2019
2019 Lung Infection Symposium - Fayed IV 2
Objectives
• What is the guideline and best practice in treatment of NTM lung disease
• New therapy available for NTM lung disease
Management of NTM
• Non pharmacological therapy
‒ Tobacco cessation
‒ Airway clearance
‒ Reduce exposure
‒ Exercise and nutrition
• Pharmacological therapy include Multidrug therapy
• Frequent monitoring
‒ Side effect
‒ Clinical symptoms
‒ Microbiological and culture conversion
‒ Radiological improvement
10/26/2019
2019 Lung Infection Symposium - Fayed IV 3
Non pharmacological therapy
• Tobacco cessation if applicable
• Airway clearance
• Reduce exposure
• exercise and improve nutrition
Pharmacological therapy
• Initiating medication
‒ Oral therapy
‒ Inhaler therapy
‒ IV therapy
Frequent monitoring
10/26/2019
2019 Lung Infection Symposium - Fayed IV 4
Non pharmacological therapy
Airway clearance
Airway clearance
10/26/2019
2019 Lung Infection Symposium - Fayed IV 5
Airway clearance
Airway clearance
Nebulized solutions
• Hypertonic saline
• Bronchodilators
Assistance
• Manual percussion
• Postural positioning
10/26/2019
2019 Lung Infection Symposium - Fayed IV 6
Exposure reduction
Avoid hot tubs
Change and clean shower heads
• Use filters < 0.45 microns on taps and showerheads
• Change showerheads every month or disinfect in bleach for 30 min
• Use large holes in showerhead
Avoid dust inhalation when gardening or cleaning in homes.
Wet soil to reduce aerosols.
Exposure reduction
•Avoid Humidifier •Regular cleaning – cleaning or disinfection (undiluted household bleach for 30 minutes)
10/26/2019
2019 Lung Infection Symposium - Fayed IV 7
Guideline therapy
1.Am J Respir Crit Care Med Vol 175. pp 367–416, 20072. Haworth CS, et al. Thorax 2017;72:iii1–ii64. doi:10.1136/thoraxjnl-2017-210927
Drug therapy for MAC disease involves multiple drugs
• Choice of regimen depends on the species
• Sensitivity is needed to direct good regimen
10/26/2019
2019 Lung Infection Symposium - Fayed IV 8
Slow growing NTM therapy
M.Avium complex (MAC)
• M.chimaera
• M.Avium
• M.Intercellulare
M. kansasii
M. xenopi
10/26/2019
2019 Lung Infection Symposium - Fayed IV 9
Rapid growing NTM therapy
M. abscessus
10/26/2019
2019 Lung Infection Symposium - Fayed IV 10
M. xenopi.
Non-severe pulmonary disease Severe pulmonary disease
1. Rifampicin 2. Ethambutol 3. Azithromycin 250mg daily4. Moxifloxacin 400mg daily or isoniazid
300mg
1. Rifampicin 2. Ethambutol 3. Azithromycin 250mg daily 4. Moxifloxacin 400mg daily or isoniazid
300mg (+pyridoxine 10mg) daily and5. Consider intravenous amikacin for up
to 3 months or nebulised amikacin
4 drugs therapy
Haworth CS, et al. Thorax 2017;72:ii1–ii64. doi:10.1136/thoraxjnl-2017-210927
10/26/2019
2019 Lung Infection Symposium - Fayed IV 11
Mycobacterium abscessus
Treatment consists of initial phase followed by continuous phase
• Sensitivity classified into 2 groups
‒ Clarithromycin sensitive isolates or inducible macrolide-resistant isolates erm (41)
‒ Constitutive macrolide-resistant isolates
Haworth CS, et al. Thorax 2017;72:ii1–ii64. doi:10.1136/thoraxjnl-2017-210927
Initial phase for both groups (sensitive and resistant) 3 IV antibiotics for 4 weeks
• IV Amikacin plus
• IV tigecycline plus
• IV Imipenem
10/26/2019
2019 Lung Infection Symposium - Fayed IV 12
Continuation phase (sensitive group)
• Nebulized Amikacin plus
• Oral azithromycin plus one the following (antibiotics guided by drug susceptibility results and patient tolerance)
‒ Clofazimine
‒ linezolid
‒ minocycline
‒ Moxifloxacin
‒ Trimethoprim-sulfamethoxazol
Continuation phase (Resistant group)
• Nebulized Amikacin plus
• 2–4 of the following antibiotics guided by drug susceptibility results
‒ clofazimine
‒ minocycline
‒ moxifloxacin
‒ Trimethoprim-sulfamethoxazole
10/26/2019
2019 Lung Infection Symposium - Fayed IV 13
Follow up
Frequent monitoring
• Clinical improvement and side effect (usually 1-2 month then after 3-4 month if stable)
• Hearing testing every 6 month
• Eye exam especially if daily ethambutol
• Caution with fluoroquinolone related tendinopathy
• Neuropathy with linezolid
Follow up
• Laboratory monitoring
‒ CBC and CMP (1-2 month then every 3-4 month if stable)
‒ Amikacin level if IV is given
• Microbiological monitoring
‒ Sputum culture to demonstrate culture conversion (therapy is usually 12-18 month after culture conversion)
• Radiological monitoring
‒ CT scan to demonstrate improvement (frequency varies)
10/26/2019
2019 Lung Infection Symposium - Fayed IV 14
Novel therapy
Arikayce, FDA approved for limited population in Sept 2018
• Limitation of use: Amikacin oral inhalation has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy
10/26/2019
2019 Lung Infection Symposium - Fayed IV 15
10/26/2019
2019 Lung Infection Symposium - Fayed IV 16
10/26/2019
2019 Lung Infection Symposium - Fayed IV 17
Role of Surgery
Surgical resection for limited pulmonary disease may be curative, however, the decision to perform surgery should be made by clinicians with experience in the treatment of nontuberculous mycobacterial disease
Indications for considering lung surgery include poor response to drug therapy and significant disease-related complications, such as hemoptysis.
Thoracic surgery for M. abscessus infection, in particular, may be associated with significant complications even in expert hands and should only be performed in centers with extensive experience
10/26/2019
2019 Lung Infection Symposium - Fayed IV 18
Summary
Treatment is multifactorial
• Non pharmacological therapy
‒ Airway clearance
‒ Tobacco cessation
‒ Reduce exposure
‒ Exercise and nutrition
• Pharmacological therapy include Multidrug therapy
• Frequent monitoring
‒ Side effect
‒ Clinical symptoms
‒ Microbiological and culture conversion
‒ Radiological improvement
Thank you!